



new



Partners in
Bleeding Disorders
Education

Understanding Hemophilia – ***NOW AVAILABLE***

The [Partners in Bleeding Disorders Education Program](#) is excited to announce the launch of a new version of “**Understanding Hemophilia**.” This 6-part online learning activity aims to enable clinicians at U.S. Hemophilia Treatment Centers (HTCs) to gain knowledge and develop expertise on hemophilia, including pathogenesis and inheritance, symptoms and sequelae, management with factor concentrates and emicizumab, inhibitor development and management, and carrier considerations.

Intended for clinical staff at U.S. HTCs who wish to develop an understanding of basic concepts of hemophilia, “Understanding Hemophilia” is accredited for nurses, nurse practitioners, and physician assistants, through the University of Nebraska Medical Center College of Nursing Continuing Nursing Education department; and includes contact hours related to pharmacotherapeutic content required for most nurse practitioners to maintain licensure.

To complete this learning activity, please register for an account or login at www.PartnersPRN.org. The activity is listed under “[Online Education](#).” To receive credit, you must complete all 6 parts of the activity, including completion of a posttest and program evaluation form. Partial credit cannot be granted. Individuals who completed a previous version of “Understanding Hemophilia,” are eligible to complete this new program and to receive credit for doing so.

This activity expires February 7, 2022. Learners must complete it before that date.

Questions?

Please contact Natalie Duncan, MPH, at nduncan@ihtc.org.

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is provided for **2.0** contact hours under ANCC criteria.

This activity is provided for **0.3** contact hours related to pharmacotherapeutic content.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 2.00 AAPA Category 1 CME credits. Approval is valid for one year from 02/07/2020. PAs should only claim credit commensurate with the extent of their participation.

